Red Meat Consumption and Mortality
Results From 2 Prospective Cohort Studies
Background Red meat consumption has been associated with an increased risk of chronic diseases. However, its relationship with mortality remains uncertain.
Adding foods rich in specific amino and fatty acids to the diets of youth with Type 1 diabetes kept them producing some of their own insulin for up to two years after diagnosis, said researchers at the Gillings School of Global Public Health at the University of North Carolina at Chapel Hill."
The youth still required supplemental insulin, but they may have reduced risk of diabetes complications by continuing to produce some of their own insulin, said Elizabeth Mayer-Davis, professor of nutrition at Gillings and medicine at UNC's School of Medicine, who led the study of more than 1,300 youth. "This also opens the door for a new approach that could really benefit the lives of these children."
The study, "Nutritional Factors and Preservation of C-Peptide in Youth with Recently Diagnosed Type 1 Diabetes," was published in the July 2013 issue of the journal Diabetes Care.
The participating youngsters, ranging from toddlers up to age 20, are part of a multi-center "SEARCH for Diabetes in Youth," the largest U.S. study of childhood diabetes. Mayer-Davis is national co-chair of SEARCH, funded by the national Centers for Disease Control and Prevention and the National Institutes of Health.
Type 1 diabetes is almost always diagnosed between infancy and young adulthood, according to the American Diabetes Association. The body's pancreas is unable to produce adequate amounts of the hormone insulin, required to metabolize food properly and create energy for the body's cells.
Leucine, one of the branched-chain amino acids researchers looked at, is known to stimulate secretion. It is found in dairy products, meats, soy products, eggs, nuts and products made with whole wheat. Long-chain omega-3 fatty acids are found in fatty fish such as salmon.
The researchers analyzed how much (if any) insulin the subjects were producing up to two years after their diagnosis and compared this with nutritional intake.
Mayer-Davis noted the study reflects subjects eating actual foods rich in these nutrients, not taking supplements.
Pada diabetesi tipe 2, konsumsi polong (low glicemic index diet) memperbaiki kontrol glikemik dan menurunkan risiko penyakit jantung koroner.
Background Legumes, including beans, chickpeas, and lentils, are among the lowest glycemic index (GI) foods and have been recommended in national diabetes mellitus (DM) guidelines. Yet, to our knowledge, they have never been used specifically to lower the GI of the diet. We have therefore undertaken a study of low-GI foods in type 2 DM with a focus on legumes in the intervention.
Methods A total of 121 participants with type 2 DM were randomized to either a low-GI legume diet that encouraged participants to increase legume intake by at least 1 cup per day, or to increase insoluble fiber by consumption of whole wheat products, for 3 months. The primary outcome was change in hemoglobin A1c (HbA1c) values with calculated coronary heart disease (CHD) risk score as a secondary outcome.
Results The low-GI legume diet reduced HbA1c values by −0.5% (95% CI, −0.6% to −0.4%) and the high wheat fiber diet reduced HbA1c values by −0.3% (95% CI, −0.4% to −0.2%). The relative reduction in HbA1c values after the low-GI legume diet was greater than after the high wheat fiber diet by −0.2% (95% CI, −0.3% to −0.1%; P < .001). The respective CHD risk reduction on the low-GI legume diet was −0.8% (95% CI, −1.4% to −0.3%; P = .003), largely owing to a greater relative reduction in systolic blood pressure on the low-GI legume diet compared with the high wheat fiber diet (−4.5 mm Hg; 95% CI, −7.0 to −2.1 mm Hg; P < .001).
Conclusion Incorporation of legumes as part of a low-GI diet improved both glycemic control and reduced calculated CHD risk score in type 2 DM.
Assessing Biochemical Data of Adult, Child and Adolescent Vegetarians
Assessing Vitamin B-12 Status of Adult, Child and Adolescent Vegetarians
Assessing Food and Nutrient Intake of Adult Vegetarians
Assessing Micronutrient Intake of Adult Vegetarians
Micronutrient Intake in Adolescent and Adult Vegetarians During Pregnancy
Micronutrient Intake in Pregnant Adolescent and Adult Vegetarians
Vitamin B-12 Intake in Pregnant Adolescent and Adult Vegetarians
Hyperlipidemia Treatment with a Vegetarian Diet for Adults
Treating Hyperlipidemia with a Vegetarian Diet for Adults
Overweight and Obesity Treatment with a Vegetarian Diet for Adults
Treating Overweight and Obesity with a Vegetarian Diet for Adults
Type 2 Diabetes Treatment with a Vegetarian Diet for Adults
Treating Type 2 Diabetes with a Vegetarian Diet for Adults
Information sourced from Journal Watch:
New Position Statement for Managing Type 2 Diabetes
A one-size-fits-all approach is rejected.
The American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) have published a new position statement entitled, "Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach." The document outlines basic elements of lifestyle modification, oral agents, noninsulin injectable agents, and insulin, and provides management tips that even experienced clinicians might find helpful. Two aspects of the report are particularly noteworthy:
Comment: Many clinicians talk about getting their patients with type 2 diabetes "to goal," as if a single, evidence-based target was applicable to every patient. Others talk about being "dinged" by real or imagined organizations if their patients' HbA1c levels are not in a certain range. In contrast, this position statement supports a more-reasoned approach that involves shared decision making and flexible goals. In a worthwhile accompanying editorial, the author describes the process that resulted in this position statement. One note: Nine of the 10 authors of the statement each have financial ties to numerous pharmaceutical companies.
— Allan S. Brett, MD
Published in Journal Watch General Medicine July 24, 2012
CITATION(S):
Inzucchi SE et al. Management of hyperglycemia in type 2 diabetes: A patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012 Jun; 35:1364. [Free full-text PDF | PubMed® abstract]
Cefalu WT. American Diabetes Association–European Association for the Study of Diabetes position statement: Due diligence was conducted. Diabetes Care 2012 Jun; 35:1201. [Free full-text PDF | PubMed® abstract]
Copyright © 2012. Massachusetts Medical Society. All rights reserved.
The above message comes from "Journal Watch", who is solely responsible for its content.
Information sourced from Journal Watch:
What Therapy Is Best for Diabetes After Metformin Fails?
In three trials, researchers assess options for second-line diabetes therapy.
Metformin is accepted widely as first-line treatment for patients with type 2 diabetes, but no clear guidelines exist on how to proceed when metformin monotherapy fails. In three new industry-supported studies, researchers compared available second-line treatments.
In an open-label study, 1029 adults with glycosylated hemoglobin (HbA1c) levels between 6.5% and 9.0% while taking metformin were randomized to add either the glucagon-type peptide-receptor agonist exenatide (Byetta; 5–10 µg subcutaneously twice daily) or the sulfonylurea glimepiride (titrated to maximum tolerated daily dose). During 4 years of follow-up, significantly fewer exenatide recipients than glimepiride recipients (41% vs. 54%) reached the primary endpoint of treatment failure (HbA1c level >9% after 3 months of treatment, or HbA1c level >7% at two consecutive readings after 6 months of treatment). Significantly more patients in the exenatide group than in the glimepiride group reached a target HbA1c level of <7% (44% vs. 31%). Patients who received exenatide lost a mean of 3.3 kg, whereas those who received glimepiride gained a mean of 1.2 kg — a significant difference. Hypoglycemia occurred significantly more often in patients taking glimepiride.
In another open-label trial, researchers randomized 515 adults with HbA1c levels between 7% and 11% while taking metformin to add either once-daily insulin glargine (Lantus; titrated to a fasting glucose level of 72–99 mg/dL) or the dipeptidyl peptidase-4 (DPP-4) inhibitor sitagliptin (Januvia; 100 mg once daily). After 24 weeks, patients who received insulin glargine had a significantly greater reduction in mean HbA1c level than did those who received sitagliptin (–1.7% vs. –1.1%), and more patients who received insulin glargine reached the HbA1c target of 7% (68% vs. 42%). Mean body weight increased slightly in the insulin glargine group and decreased slightly in the sitagliptin group, and significantly more hypoglycemic events occurred in the insulin glargine group (4.2 vs. 0.5 per patient-year).
In the third trial, researchers randomized 1551 patients with HbA1c levels between 6.5% and 10.0% who were taking metformin alone to the DPP-4 inhibitor linagliptin (Tradjenta; 5 mg daily) or to glimepiride (1–4 mg daily, titrated to fasting plasma glucose ≤110 mg/dL). After 2 years, average HbA1c level was –0.16% in the linagliptin group and –0.36% in the glimepiride group. Thirty percent of patients taking linagliptin and 35% of those taking glimepiride reached HbA1c levels <7%. Average body weight decreased slightly with linagliptin and rose slightly with glimepiride; hypoglycemic events occurred in 7% of patients taking linagliptin and in 36% of those taking glimepiride.
Comment: The choice of diabetes therapies is complex, involving patient acceptance, efficacy, and safety. These trials were limited to surrogate endpoints, and all were industry-sponsored (by the makers of exenatide, insulin glargine, and linagliptin, respectively); also, the insulin glargine–sitagliptin trial was very brief. Nevertheless, these trials highlight some of the strengths and weaknesses of the various options for second-line diabetes therapy; the long-term effects of these therapies on glucose metabolism and clinical endpoints remain to be elucidated.
— Bruce Soloway, MD
Published in Journal Watch General Medicine July 10, 2012
CITATION(S):
Gallwitz B et al. Exenatide twice daily versus glimepiride for prevention of glycaemic deterioration in patients with type 2 diabetes with metformin failure (EUREXA): An open-label, randomised controlled trial. Lancet 2012 Jun 16; 379:2270. [Medline® Abstract]
Aschner P et al. Insulin glargine versus sitagliptin in insulin-naive patients with type 2 diabetes mellitus uncontrolled on metformin (EASIE): A multicentre, randomised open-label trial. Lancet 2012 Jun 16; 379:2262. [Medline® Abstract]
Gallwitz B et al. 2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: A randomised, double-blind, non-inferiority trial. Lancet 2012 Jun 27; [e-pub ahead of print]. [Medline® Abstract]
Copyright © 2012. Massachusetts Medical Society. All rights reserved.
The above message comes from "Journal Watch", who is solely responsible for its content.